|
|
|
|
|
|
By Justin Culbertson and Adam Lohr, RSM US LLP | RSM is back for the third consecutive year to provide an outlook analysis of the cell and gene therapy market. This article discusses the 2024 state of the macroeconomy, its effects on cell and gene therapy companies, growing approval pipelines and approvals, funding factors, and the unique prospects for the market. |
|
|
Creative Outsourcing Strategies, But Fill/Finish Still A Concern | By Louis Garguilo, Chief Editor, Outsourced Pharma | Chief Editor Louis Garguilo wraps up his discussions with Thomas Rademacher, CEO, Emergex Vaccines, focusing on strategies that mix internal capacity, facility purchases, CDMOs, new technologies, and challenges with fill/finish outsourcing. |
|
|
|
|
mRNA/saRNA Manufacturing RNA Production And Manufacturing | Q&A | Aldevron | Venkata Indurthi, Ph.D., discusses key considerations for the production of RNA and strategies for successful scaling for commercial manufacture. Learn more about messenger RNA and self-amplifying RNA manufacturing processes. |
|
|
Scale Up Strategy For Oncolytic HSV-1 Vector Manufacturing | Case Study | By Lingjing Tang, Jun Wang, Shiyi Mei, Zhengrui Xiong, Zihao Fang, Han Gao, Houliang Wei, and Weiran Shen, OBiO Tech | Discover how a novel, large-scale production method for herpes simplex virus type-1 (HSV-1) vectors has the potential to accelerate the progress of gene therapy and bring it closer to widespread application. |
|
|
Insights Into GMP Manufacturing Of RNA-LNP Drug Products | Article | Precision NanoSystems | Explore key considerations for manufacturing RNA-LNP drug products surrounding process and analytical development, automation, environmental monitoring, facility design, and strategic collaborations. |
|
|
The Changing Vaccine Development Landscape | Article | FUJIFILM Diosynth Biotechnologies | Review the different technologies that are being used to develop next-generation vaccines and the challenges and opportunities that these technologies present. |
|
|
|
|
| Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan | Orca Bio's CMO, Dr. Scott McClellan, joins Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. Learn about the company’s plan to potentially lower the risk of GvHD as well as Orca-T, the investigational high-precision allogeneic cell therapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies. Listen now and subscribe so you never miss an episode! |
|
|
|
|
A New Player With A Long History | Andelyn Biosciences | Leveraging more than 15 years in the field, Andelyn Biosciences provides custom development and manufacturing of AAV vectors for gene therapy as a full-service concept-to-commercialization cGMP CDMO. |
|
|
OUTSOURCED PHARMA CAPACITY UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
